AB1115 STUDY DESIGN AND FULL BASELINE SAMPLE CHARACTERISTICS OF PATIENTS FROM THE 24-MONTH MULTINATIONAL PROSPECTIVE PSORIATIC ARTHRITIS OBSERVATIONAL STUDY OF PERSISTENCE OF TREATMENT (PRO-SPIRIT)
Authors: J. Morel, E. Lubrano, W. Tillett, R. Alten, L. E. Kristensen, V. Chandran, T. Treuer, J. Burke, À. Martínez-Ferrer, T. Holzkaemper, N. Gullick
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Ixekizumab (IXE), an Interleukin (IL)-17A inhibitor (i), approved for the treatment (tx) of Psoriasis (Pso), psoriatic arthritis (PsA) and axSpA (rad/non rad) have limited real-world data. PRO-SPIRIT is the first large, prospective observational study for IXE in patients (pts) with PsA who start a new biologic/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD), with a primary endpoint of persistence at 24 months (M). <h3>Objectives</h3> To describe baseline (BL) characteristics of pts enrolled in PRO-SPIRIT. <h3>Methods</h3> PRO-SPIRIT enrolled pts December 2019-June 2022 in FR, ES, IT, DE, UK, and CA, who started a new b/tsDMARD, approved for PsA. Tx groups are; IXE, secukinumab (SEC), IL-12/-23i, IL-23i, tumor necrosis factor inhibitor (TNFi), Janus kinase inhibitors (JAKi), and Phosphodiesterase-4 inhibitor (PDE4i). Pts' demographic, disease activity, and tx characteristics were recorded at BL, effectiveness outcomes and tx changes at 3, 6,12,18, and 24M. BL descriptive statistics are shown. <h3>Results</h3> The analysis included 1207 pts (2 pts with other tx not shown below). Most were female, had mean age 52.4yrs, poly/oligo-arthritis and enthesitis/dactylitis in similar proportions except for enthesitis in IL12/23i and IL-23i pts. Pts started on IXE had long disease duration (9.2yrs). Most had prior b/tsDMARDs (69.5%) and 38.7% had active PsO similar to SEC pts. For TNFi pts, mean disease duration was 6.5yrs, 30.8% had received prior b/tsDMARDs, and 30.4% had active PsO. IL-23i pts (n=57) were typified by long disease duration (8.7yrs), high proportions of PsO (50.9%)/nail PsO (50.9%) and prior b/tsDMARD use (78.9%). JAKi pts had long (9.2yrs) disease duration, 72.2% prior b/tsDMARDs experience, and 26.2% had active PsO. IXE and IL23i pts were more often treated on monotherapy. <h3>Conclusion</h3> In PRO-SPIRIT, pts starting IXE showed active PsA, with both joint and often skin involvement, and were mostly treated with monotherapy after failing several b/tsDMARDs. TNFis were often used as 1<sup>st</sup> line therapy alongside csDMARDs. <h3>Acknowledgements</h3> This study was funded by Eli Lilly and Company. Mr. Alan Ó Céilleachair, an employee of Eli Lilly and Company, provided scientific writing support for this submission. <h3>Disclosure of Interests</h3> Jacques Morel Speakers bureau: Biogen, Amgen, Bristol Myers Squib, Eli Lilly and Company, Novartis, Sanofi, MSD, Mylan, Fresenius Kabi, Roche, Union Chimique Belge, Janssen, Medac, and Nordic Pharma, Consultant of: Pfizer, AbbVie, Boerhinger Ingelheim, Galapagos, and GSK, Grant/research support from: Fresenius Kabi, Ennio Lubrano Speakers bureau: Abbvie, Janssen Cilag, Lilly, UCB, Pfizer, and Novartis, William Tillett Speakers bureau: AbbVie, Amgen, Eli Lilly and Company, GSK, Janssen, Novartis, Pfizer, and UCB., Consultant of: Abbvie, Amgen, Eli Lilly and Company, GSK, Janssen, Novartis, Ono Pharma, Pfizer, and UCB., Grant/research support from: Janssen, UCB, Pfizer, and Eli Lilly and Company., Rieke Alten Speakers bureau: AbbVie, BMS, Celltrion, Galapagos, Eli Lilly and Company, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, BMS, Celltrion, Galapagos, Eli Lilly and Company, Novartis, Pfizer, Roche, and UCB, Lars Erik Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly and Company, and Janssen, Consultant of: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly and Company, and Janssen, Grant/research support from: Pfizer, AbbVie, UCB, Gilead, Biogen, Novartis, Eli Lilly and Company, and Janssen, Vinod Chandran Consultant of: AbbVie, Eli Lilly, Novartis, Amgen, and Janssen, Grant/research support from: AbbVie, Tamas Treuer Shareholder of: Minor shareholder, Employee of: Eli Lilly and Company, Joanna Burke Employee of: Joanna Burke is contracted to Eli Lilly and Company, À Martínez-Ferrer Grant/research support from: Eli Lilly and Company, Thorsten Holzkaemper Shareholder of: Minor shareholder Eli Lilly and Company, Employee of: Eli Lilly and Company, Nicola Gullick Speakers bureau: AbbVie, Eli Lilly and Company, Janssen, Novartis, UCB, Consultant of: AbbVie, Janssen, Novartis, UCB, Grant/research support from: Astra Zeneca, AbbVie, Eli Lilly and Company, Izana, Novartis.